التفاصيل البيبلوغرافية
| العنوان: |
Ten-year survival impact of FDA warning on power morcellation in occult uterine leiomyosarcoma diagnosed after minimally invasive surgery. |
| المؤلفون: |
Dong Hoon Suh, Nam Kyeong Kim, Min Kyung Kim, Ki Eun Seon, Eun Ji Nam, Soo Jin Park, Hee Seung Kim, Ji Geun Yoo, Sung Jong Lee, Myeong-Seon Kim, Yoo-Young Lee, Seung-Hyuk Shim, Jin Lee, A., Eun Bi Jang, Suk-Joon Chang, Joo-Hyuk Son, Tae Wook Kong, Jeeyeon Kim |
| المصدر: |
Journal of Gynecologic Oncology; 2024 Supplement, Vol. 35, p48-49, 2p |
| مصطلحات موضوعية: |
MINIMALLY invasive procedures, MYOMECTOMY, SURGICAL margin, OCCULTISM, SURVIVAL rate, SMOOTH muscle tumors, OVERALL survival, LEIOMYOSARCOMA |
| الشركة/الكيان: |
UNITED States. Food & Drug Administration |
| مستخلص: |
Objective: To evaluate the impact of 2014 Food and Drug Administration (FDA) warning against power morcellation (PM) on survival outcomes of patients with incidentally found uterine leiomyosarcoma (uLMS) after minimally invasive surgery (MIS). Methods: Patients who underwent hysterectomy or myomectomy via MIS for presumed uterine leiomyoma and were pathologically diagnosed with stage I uLMS between 2003 and 2022 were retrospectively reviewed. Survival outcomes and clinicopathologic factors were compared between the 2 groups of which the initial MIS was performed before and after the FDA statement: pre-FDA vs. post-FDA. Results: Thirty-two women were included: 12 in the pre-FDA group and 20 in the post-FDA group. Median follow-up period was 63.1 months. There were no significant differences in stage, type of surgery, tumor size, mitotic counts, resection margin status, lymphovascular space invasion, additional surgery, and adjuvant treatment between the 2 groups. The frequency of PM decreased in the post-FDA group compared with the pre-FDA group (33.3% vs. 10.0%, p=0.165), while endobag use (16.7% vs. 50.0%, p=0.075) and umbilical knife morcellation (KM) (0.0% vs. 20.0%, p=0.271) increased despite statistical insignificance. Of note, however, vaginal KM was significantly increased between the 2 period (16.7% vs. 65.0%, p=0.012). There was significant difference neither in recurrence-free survival (RFS) (2-year RFS rate, 72.7% and 63.3%; p=0.451) nor in overall survival (p=0.348) between the 2 groups. Conclusion: Despite seemingly decreased use of PM and increase of KM with endobag use for the last 10 years after the FDA warning compared with pre-FDA era, we failed to demonstrate significant survival improvements in patients who were incidentally diagnosed with uLMS after MIS between the 2 periods. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Gynecologic Oncology is the property of Korean Society of Gynecologic Oncology & Colposcopy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder